News Overview

November 2, 2009
Successful purchase of trait platform with extensive product pipeline:
Bayer CropScience completes acquisition of biotech company Athenix Corp.
 » more
October 27, 2009
News Conference Call for the Third Quarter of 2009
Address by Werner Wenning
 » more
October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
 » more
  1:15 min.
October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
 » more
September 22, 2009
Once again included in the Carbon Disclosure Leadership Index
Bayer honored as world’s best company in climate protection
 » more
  1:19 min.
September 17, 2009
Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
 » more
September 15, 2009
Bayer Supervisory Board decides company’s future management line-up:
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
 » more
September 4, 2009
Bayer again included in the Dow Jones Sustainability World Index:
Bayer remains “best in class” in sustainability
 » more
August 30, 2009
Bayer Committed to Prevention of Arterial Thrombosis:
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
 » more
August 19, 2009
Trait platform with extensive product pipeline to deliver innovative solutions for farmers:
Bayer CropScience acquires US biotech company Athenix Corp.
 » more
  1:17 min.
July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
 » more
July 14, 2009
New Drug Application for Rivaroxaban in the U.S.:
Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA
 » more
July 9, 2009
Expansion of diabetes portfolio in growth market China:
Bayer acquires exclusive rights to Bioton’s insulin SciLin®
 » more
  1:14 min.
more News


top
top
top
top
top
top
top
top
top
Search
Search
Stockholders' Newsletter Third Quarter 2009
 
Stockholders' Newsletter Second Quarter 2009
 
Stockholders' Newsletter First Quarter 2009
 
Annual Report 2008
 
All Financial Reports
 
All Bayer Websites
 
Service
 
 
 
 
RSS